2026-04-13T00:52:19Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4767642025-10-27T12:20:51Zcom_2072_98col_2072_378192

00925njm 22002777a 4500 dc Perry, M.S. author Scheffer, I.E. author Sullivan, J. author Brunklaus, A. author Boronat, Susana author Wheless, J.W. author Laux, L. author Patel, A.D. author Roberts, C.M. author Dlugos, D. author Holder, D. author Knupp, K.G. author Lallas, M. author Phillips, S. author Segal, E. author Smeyers, P. author Lal, D. author Wirrell, E. author Zuberi, Sameer M author Brünger, T. author Wojnaroski, M. author Maru, B. author O'Donnell, P. author Morton, M. author James, Emma S. author Vila, M.C. author Huang, N. author Gofshteyn, J.S. author Rico, S. author Universitat Autònoma de Barcelona author 2024 Dravet syndrome (DS) is a developmental and epileptic encephalopathy characterized by high seizure burden, treatment-resistant epilepsy, and developmental stagnation. Family members rate communication deficits among the most impactful disease manifestations. We evaluated seizure burden and language/communication development in children with DS. ENVISION was a prospective, observational study evaluating children with DS associated with SCN1A pathogenic variants (SCN1A+ DS) enrolled at age ≤5 years. Seizure burden and antiseizure medications were assessed every 3 months and communication and language every 6 months with the Bayley Scales of Infant and Toddler Development 3rd edition and the parent-reported Vineland Adaptive Behavior Scales 3rd edition. We report data from the first year of observation, including analyses stratified by age at Baseline: 0:6-2:0 years:months (Y:M; youngest), 2:1-3:6 Y:M (middle), and 3:7-5:0 Y:M (oldest). Between December 2020 and March 2023, 58 children with DS enrolled at 16 sites internationally. Median follow-up was 17.5 months (range =.0-24.0), with 54 of 58 (93.1%) followed for at least 6 months and 51 of 58 (87.9%) for 12 months. Monthly countable seizure frequency (MCSF) increased with age (median [minimum-maximum] = 1.0 in the youngest [1.0-70.0] and middle [1.0-242.0] age groups and 4.5 [.0-2647.0] in the oldest age group), and remained high, despite use of currently approved antiseizure medications. Language/communication delays were observed early, and developmental stagnation occurred after age 2 years with both instruments. In predictive modeling, chronologic age was the only significant covariate of seizure frequency (effect size =.52, p =.024). MCSF, number of antiseizure medications, age at first seizure, and convulsive status epilepticus were not predictors of language/communication raw scores. In infants and young children with SCN1A+ DS, language/communication delay and stagnation were independent of seizure burden. Our findings emphasize that the optimal therapeutic window to prevent language/communication delay is before 3 years of age. Dravet syndrome ENVISION Communication/language delays Developmental and epileptic encephalopathy Natural history study Severe communication delays are independent of seizure burden and persist despite contemporary treatments in SCN1A+ Dravet syndrome : Insights from the ENVISION natural history study